DK0996717T3 - Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination - Google Patents

Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination

Info

Publication number
DK0996717T3
DK0996717T3 DK98946321T DK98946321T DK0996717T3 DK 0996717 T3 DK0996717 T3 DK 0996717T3 DK 98946321 T DK98946321 T DK 98946321T DK 98946321 T DK98946321 T DK 98946321T DK 0996717 T3 DK0996717 T3 DK 0996717T3
Authority
DK
Denmark
Prior art keywords
antigen
vaccination
influenza antigen
influenza
relates
Prior art date
Application number
DK98946321T
Other languages
Danish (da)
English (en)
Inventor
Walter Fiers
Sabine Neirynck
Jou Willy Min
Original Assignee
Vlaams Interuniv Inst Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8228624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0996717(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vlaams Interuniv Inst Biotech filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of DK0996717T3 publication Critical patent/DK0996717T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK98946321T 1997-08-05 1998-08-05 Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination DK0996717T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97202434 1997-08-05

Publications (1)

Publication Number Publication Date
DK0996717T3 true DK0996717T3 (da) 2006-04-10

Family

ID=8228624

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98946321T DK0996717T3 (da) 1997-08-05 1998-08-05 Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination

Country Status (10)

Country Link
US (1) US7732130B2 (enExample)
EP (1) EP0996717B1 (enExample)
JP (2) JP5132851B2 (enExample)
AT (1) ATE312172T1 (enExample)
AU (1) AU745951B2 (enExample)
CA (1) CA2297786C (enExample)
DE (1) DE69832706T2 (enExample)
DK (1) DK0996717T3 (enExample)
ES (1) ES2255181T3 (enExample)
WO (1) WO1999007839A2 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731972B1 (en) 2000-02-04 2010-06-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
ES2255181T3 (es) 1997-08-05 2006-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antigeno inmunoprotector contra la gripe y su uso en vacunacion.
WO2000032227A2 (en) 1998-11-30 2000-06-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use
GB0008582D0 (en) * 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
AU5533601A (en) * 2000-04-14 2001-10-30 Wisconsin Alumni Res Found Viruses comprising mutation ion channel protein
EP1282640A2 (en) * 2000-05-01 2003-02-12 Powderject Vaccines, Inc. Nucleic acid immunization
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
GB0025229D0 (en) * 2000-10-14 2000-11-29 Adprotech Ltd Veterinary immunisation vectors
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
ES2335979T3 (es) 2001-09-14 2010-04-07 Cytos Biotechnology Ag Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
GB0204154D0 (en) * 2002-02-22 2002-04-10 Adprotech Ltd Cat immunisation vectors
TW200407161A (en) * 2002-03-13 2004-05-16 Gemini Science Inc Human monoclonal antibodies to influenza M2 protein and method of making and using same
CN102061288A (zh) 2002-07-17 2011-05-18 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
IN2008CN05409A (enExample) 2002-07-18 2015-10-02 Cytos Biotechnology Ag
CA2492930C (en) 2002-07-19 2013-01-08 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
CA2522081C (en) * 2003-04-23 2013-01-29 Wisconsin Alumni Research Foundation Recombinant influenza viruses holding a mutation in a transmembrane protein gene
ATE414535T1 (de) * 2003-06-23 2008-12-15 Baxter Int Trägerproteine für impfstoffe
KR20070086344A (ko) 2004-11-19 2007-08-27 위스콘신 얼럼나이 리서어치 화운데이션 탠덤 전사 유닛을 갖는 재조합 인플루엔자 벡터
AU2005313026B2 (en) 2004-12-06 2011-09-08 Kyowa Hakko Kirin Co., Ltd. Human monoclonal antibodies to influenza M2 protein and methods of making and using same
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
WO2007056266A2 (en) * 2005-11-07 2007-05-18 Sidney Kimmel Cancer Center Cd40 ligand fusion protein vaccine
CA2632483C (en) 2005-12-06 2014-11-25 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved influenza vaccine
EP1991264B1 (en) 2006-03-07 2015-01-07 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
EP2010557B1 (en) 2006-03-31 2014-02-26 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
EP2043681B1 (en) 2006-07-14 2015-10-07 Sanofi Pasteur Biologics, LLC Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
WO2008100290A2 (en) 2006-09-29 2008-08-21 Sanofi Pasteur Biologics Co Recombinant rhinovirus vectors
WO2008058396A1 (en) * 2006-11-15 2008-05-22 Folia Biotech Inc. Papaya mosaic virus-based vaccines for influenza
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
MX2010001284A (es) 2007-08-02 2010-08-31 Biondvax Pharmaceuticals Ltd Vacunas contra la influenza con multiepitope multimerico.
WO2009073330A2 (en) * 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
SG190562A1 (en) * 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
CA2742288A1 (en) * 2008-07-30 2010-02-04 Folia Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
EP2168987A1 (en) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain
BR112012008060A2 (pt) 2009-07-31 2016-11-22 Paxvax Inc vetores baseados em adenovírus
JP5730204B2 (ja) 2009-08-28 2015-06-03 一般財団法人化学及血清療法研究所 インフルエンザｍ２由来の改変ペプチドワクチン
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
US9109013B2 (en) 2009-10-26 2015-08-18 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
WO2011054995A2 (es) 2009-11-06 2011-05-12 Chimera Pharma, S. L. U. VACUNAS PROFILACTICAS DE GRIPE A PARTIR DE CAPSIDAS VIRALES DE BIRNAVIRUS CONTENIENDO EL ANTIGENO M2e DEL VIRUS DE LA GRIPE
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2013032942A1 (en) 2011-08-26 2013-03-07 Yoshihiro Kawaoka Influenza viruses with mutant pb2 gene segment as live attenuated vaccines
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
EP3022296B1 (en) 2013-07-15 2022-12-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
EP3103474A1 (en) * 2015-06-12 2016-12-14 Institut Pasteur Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
EP3417056A1 (en) 2016-02-19 2018-12-26 Wisconsin Alumni Research Foundation (WARF) Improved influenza b virus replication for vaccine development
JP2021500891A (ja) 2017-10-25 2021-01-14 ウィスコンシン アルムニ リサーチ ファンデイション 卵における複製のための安定化されたｈａを有する組換えインフルエンザウイルス
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919044A (en) * 1973-03-28 1975-11-11 Armour Pharma Processes for concentrating and purifying viruses and viral antigens
NZ219516A (en) * 1987-02-10 1991-02-26 Wellcome Found Fusion proteins of hbcag (hepatitis b virus core antigen)
EP0590055B1 (en) * 1991-06-19 1997-12-03 New York Medical College M-protein peptides of influenza virus as antiviral agents
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
ES2180576T3 (es) * 1993-04-27 2003-02-16 United Biomedical Inc Construcciones peptidicas de lhrh inmunogenicas y estimuladores de inmunidad universales sinteticos para vacunas.
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
WO1995004151A2 (en) * 1993-07-30 1995-02-09 Medeva Holdings B.V. Vaccine compositions containing recombinant tetc-fusion proteins
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
GB9424631D0 (en) * 1994-12-06 1995-01-25 Lynxvale Ltd Modulating the immune response
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
EP0941315B1 (en) 1996-11-26 2006-03-01 Stressgen Biotechnologies Corporation Fusion proteins containing stress proteins for inducing immune responses
ES2255181T3 (es) 1997-08-05 2006-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antigeno inmunoprotector contra la gripe y su uso en vacunacion.
US6169175B1 (en) * 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
US20020015951A1 (en) 2000-01-06 2002-02-07 Bader Joel S. Method of analyzing a nucleic acid

Also Published As

Publication number Publication date
JP2010059164A (ja) 2010-03-18
JP5132851B2 (ja) 2013-01-30
DE69832706D1 (de) 2006-01-12
EP0996717B1 (en) 2005-12-07
CA2297786A1 (en) 1999-02-18
ES2255181T3 (es) 2006-06-16
US7732130B2 (en) 2010-06-08
DE69832706T2 (de) 2006-08-10
WO1999007839A3 (en) 1999-05-14
AU745951B2 (en) 2002-04-11
US20060246092A1 (en) 2006-11-02
WO1999007839A2 (en) 1999-02-18
ATE312172T1 (de) 2005-12-15
AU9341698A (en) 1999-03-01
EP0996717A2 (en) 2000-05-03
CA2297786C (en) 2011-06-14
JP2001512748A (ja) 2001-08-28

Similar Documents

Publication Publication Date Title
DK0996717T3 (da) Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination
DK0851927T3 (da) Forbindelser til immunterapi og diagnosticering af tuberkulose
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
DK1032374T3 (da) Sphroider, fremgangsmåde og farmaceutiske præparater
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
WO2005081716A3 (en) DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
EA199900627A1 (ru) Универсальные т-клеточные эпитопы, используемые для получения антималярийных вакцин
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
DE69836976D1 (de) Neospora impstoff
DE69840326D1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
Knopf et al. Novel function of complement C3d as an autologous helper T‐cell target
HUP9802238A2 (hu) Fokozott immunizáló képességű módosított polipeptidek
WO1998040497A3 (en) An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
WO2004003009A3 (en) Francisella tularensis immunogenic proteins and dna encoding these
DE60237588D1 (de) Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion
AR010517A1 (es) Compuestos y metodos para la inmunoterapia y diagnostico de tuberculosis
DK1158050T3 (da) Human cysteinyl-leukotrienreceptor (CysLT2)